NELMAS – An international multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE (Lutathera®) to best supportive care in patients after resection of neuroendocrine liver metastases) is now open for recruitment at Imperial College London. The trial is in the setup process at numerous sites in the UK and Ireland. Sites in the EU will follow as soon as the EMA Ethics Approval for EU sites is in place. This is the first phase II surgical trial and the first RCT in an adjuvant setting.
Note. The Christie Hospital is also in the process of setting up participation in NELMAS and will be led by PI Melissa Frizzerio. Date October 2024.
